Drug Trial Radar · NCT07221084
A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Oct 28, 2025
Primary completion
Feb 7, 2026
Study completion Feb 27, 2026
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the PK profile, safety, and tolerability of atumelnant after single and multiple once daily (QD) oral doses in healthy Japanese and Caucasian adult participants.
Conditions
- Healthy Volunteers
Interventions
AtumelnantDrug
Atumelnant, tablets, once daily by mouth
PlaceboDrug
Placebo, tablets, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (Cmax)Time frame: [Time Frame: Up to Day 30]
- Pharmacokinetics (Tmax)Time frame: [Time Frame: Up to Day 30]
- Pharmacokinetics (AUC)Time frame: [Time Frame: Up to Day 30]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Crinetics Study Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.